Shopping Cart
- Remove All
- Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $113 | In Stock | |
5 mg | $289 | In Stock | |
10 mg | $463 | In Stock | |
25 mg | $787 | In Stock | |
50 mg | $1,090 | In Stock | |
100 mg | $1,480 | In Stock | |
1 mL x 10 mM (in DMSO) | $318 | In Stock |
Description | PF-06952229 is a selective inhibitor of TGFβRI. PF-06952229 can be used in studies about the treatment of solid tumors, specifically metastatic breast cancer. |
Targets&IC50 | TGFβRI: |
In vivo | In MCF-7 ER+ HER2-xenograft breast cancer tumor model, PF-06952229 (30 mg/kg; gavage) combines with Palbociclib results in an improved inhibition of pSMAD2 and a significant increase in survival[1]. |
Alias | PF06952229 |
Molecular Weight | 458.91 |
Formula | C23H24ClFN4O3 |
Cas No. | 1801333-55-0 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
Solubility Information | DMSO: 10 mg/mL (21.79 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.